Adaptive clinical trial design: has its time come?

J Natl Cancer Inst. 2010 Aug 18;102(16):1217-8. doi: 10.1093/jnci/djq319. Epub 2010 Aug 6.
No abstract available

Publication types

  • News

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Biomarkers, Tumor / genetics
  • Biomarkers, Tumor / metabolism*
  • Breast Neoplasms / drug therapy
  • Carcinoma, Non-Small-Cell Lung / drug therapy
  • Clinical Trials as Topic / standards*
  • Cyclin D1 / metabolism
  • ErbB Receptors / metabolism
  • Female
  • Humans
  • Lung Neoplasms / drug therapy
  • Mutation
  • Neoplasms / metabolism
  • Neoplasms / therapy*
  • Proto-Oncogene Proteins / metabolism
  • Proto-Oncogene Proteins B-raf / metabolism
  • Proto-Oncogene Proteins p21(ras)
  • Research Design / standards*
  • Retinoid X Receptors / metabolism
  • Vascular Endothelial Growth Factor A / metabolism
  • ras Proteins / metabolism

Substances

  • Biomarkers, Tumor
  • CCND1 protein, human
  • KRAS protein, human
  • Proto-Oncogene Proteins
  • Retinoid X Receptors
  • Vascular Endothelial Growth Factor A
  • Cyclin D1
  • ErbB Receptors
  • BRAF protein, human
  • Proto-Oncogene Proteins B-raf
  • Proto-Oncogene Proteins p21(ras)
  • ras Proteins